Home›Carbidopa And Levodopa

Carbidopa And Levodopa

Also known as: Rytary, Duopa, Dhivy, Crexont +2 more

Aromatic Amino Acid Decarboxylation InhibitorAromatic Amino AcidDOPA Decarboxylase Inhibitors

Route: Oral

Check Carbidopa And Levodopa Interactions →

18 interactions on record

Carbidopa And Levodopa has 18 known drug interactions based on U.S. FDA drug labeling data. Of these, 8 are contraindicated combinations that should be avoided entirely. 2 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Mao Inhibitors, Mao Inhibitors (Type A Or B), Metoclopramide. Patients taking Carbidopa And Levodopa should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 18
Contraindicated: 8
Major: 2
Moderate: 7
Minor: 1

Contraindicated (8)

Carbidopa And Levodopa + Mao Inhibitors— Contraindicated in patients receiving MAO inhibitors (Type A or B).
Carbidopa And Levodopa + Mao Inhibitors (Type A Or B)— Contraindicated per drug label.
Carbidopa And Levodopa + Metoclopramide— 7 DRUG INTERACTIONS Iron salts and dopamine D2 antagonists including metoclopramide: May reduce the effectiveness of car…
Carbidopa And Levodopa + Phenelzine— Nonselective MAO inhibitor use with carbidopa and levodopa is contraindicated. Discontinue at least two weeks prior to i…
Carbidopa And Levodopa + Reserpine— Use with carbidopa and levodopa is not recommended due to dopamine-depleting effects that may counteract the therapeutic…
Carbidopa And Levodopa + Selegiline— Concomitant therapy may be associated with severe orthostatic hypotension not attributable to carbidopa and levodopa alo…
Carbidopa And Levodopa + Tetrabenazine— Use with carbidopa and levodopa is not recommended due to dopamine-depleting effects that may counteract the therapeutic…
Carbidopa And Levodopa + Tranylcypromine— Nonselective MAO inhibitor use with carbidopa and levodopa is contraindicated. Discontinue at least two weeks prior to i…

Major (2)

Carbidopa And Levodopa + Papaverine— The beneficial effects of levodopa in Parkinson's disease have been reported to be reversed by papaverine.
Carbidopa And Levodopa + Phenytoin— The beneficial effects of levodopa in Parkinson's disease have been reported to be reversed by phenytoin.

Moderate (7)

Carbidopa And Levodopa + Butyrophenones— Dopamine D2 receptor antagonists may reduce the therapeutic effects of levodopa; patients should be carefully observed f…
Carbidopa And Levodopa + Iron Salts— Should be coadministered with caution; iron salts can form chelates with levodopa and carbidopa, reducing bioavailabilit…
Carbidopa And Levodopa + Isoniazid— May reduce the therapeutic effects of levodopa; patients should be carefully observed for loss of therapeutic response.
Carbidopa And Levodopa + Phenothiazines— Dopamine D2 receptor antagonists may reduce the therapeutic effects of levodopa; patients should be carefully observed f…
Carbidopa And Levodopa + Rasagiline— Selective MAO-B inhibitor may be associated with orthostatic hypotension when used concurrently; monitor patients.
Carbidopa And Levodopa + Risperidone— Dopamine D2 receptor antagonists may reduce the therapeutic effects of levodopa; patients should be carefully observed f…
Carbidopa And Levodopa + Selegiline Hydrochloride— Selective MAO-B inhibitor may be used concomitantly with carbidopa/levodopa, but concomitant therapy may be associated w…

Minor (1)

Carbidopa And Levodopa + Ropinirole— Co-administration had no effect on ropinirole steady-state pharmacokinetics. Ropinirole increased L-dopa Cmax by 20% but…

Carbidopa And Levodopa + Mao Inhibitors⛔Contraindicated

Contraindicated in patients receiving MAO inhibitors (Type A or B).

Carbidopa And Levodopa + Mao Inhibitors (Type A Or B)⛔Contraindicated

Contraindicated per drug label.

Carbidopa And Levodopa + Metoclopramide⛔Contraindicated

7 DRUG INTERACTIONS Iron salts and dopamine D2 antagonists including metoclopramide: May reduce the effectiveness of carbidopa and levodopa extended-release capsules ( 7.2 , 7.3 ) 7.1 Monoamine Oxidase (MAO) Inhibitors The use of nonselective MAO inhibitors with carbidopa and levodopa extended-release capsules is contraindicated [see Contraindications ( 4 )] . 7.2 Dopamine D2 Receptor Antagonists and Isoniazid Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone, metoclopramide) and isoniazid may reduce the effectiveness of levodopa.

Carbidopa And Levodopa + Phenelzine⛔Contraindicated

Nonselective MAO inhibitor use with carbidopa and levodopa is contraindicated. Discontinue at least two weeks prior to initiating therapy.

Carbidopa And Levodopa + Reserpine⛔Contraindicated

Use with carbidopa and levodopa is not recommended due to dopamine-depleting effects that may counteract the therapeutic benefit.

Carbidopa And Levodopa + Selegiline⛔Contraindicated

Concomitant therapy may be associated with severe orthostatic hypotension not attributable to carbidopa and levodopa alone.

Carbidopa And Levodopa + Tetrabenazine⛔Contraindicated

Use with carbidopa and levodopa is not recommended due to dopamine-depleting effects that may counteract the therapeutic benefit.

Carbidopa And Levodopa + Tranylcypromine⛔Contraindicated

Nonselective MAO inhibitor use with carbidopa and levodopa is contraindicated. Discontinue at least two weeks prior to initiating therapy.

Carbidopa And Levodopa + Papaverine⚠️Major

The beneficial effects of levodopa in Parkinson's disease have been reported to be reversed by papaverine.

Carbidopa And Levodopa + Phenytoin⚠️Major

The beneficial effects of levodopa in Parkinson's disease have been reported to be reversed by phenytoin.

Carbidopa And Levodopa + Butyrophenones🟡Moderate

Dopamine D2 receptor antagonists may reduce the therapeutic effects of levodopa; patients should be carefully observed for loss of response.

Carbidopa And Levodopa + Iron Salts🟡Moderate

Should be coadministered with caution; iron salts can form chelates with levodopa and carbidopa, reducing bioavailability.

Carbidopa And Levodopa + Isoniazid🟡Moderate

May reduce the therapeutic effects of levodopa; patients should be carefully observed for loss of therapeutic response.

Carbidopa And Levodopa + Phenothiazines🟡Moderate

Dopamine D2 receptor antagonists may reduce the therapeutic effects of levodopa; patients should be carefully observed for loss of response.

Carbidopa And Levodopa + Rasagiline🟡Moderate

Selective MAO-B inhibitor may be associated with orthostatic hypotension when used concurrently; monitor patients.

Carbidopa And Levodopa + Risperidone🟡Moderate

Dopamine D2 receptor antagonists may reduce the therapeutic effects of levodopa; patients should be carefully observed for loss of response.

Carbidopa And Levodopa + Selegiline Hydrochloride🟡Moderate

Selective MAO-B inhibitor may be used concomitantly with carbidopa/levodopa, but concomitant therapy may be associated with severe orthostatic hypotension.

Carbidopa And Levodopa + Ropinirole🟢Minor

Co-administration had no effect on ropinirole steady-state pharmacokinetics. Ropinirole increased L-dopa Cmax by 20% but did not affect AUC.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.